Literature DB >> 20523212

Xenon anaesthesia produces better early postoperative cognitive recovery than sevoflurane anaesthesia.

Alfio Bronco1, Pablo M Ingelmo, Michele Aprigliano, Marta Turella, Emre Sahillioğlu, Mario Bucciero, Marta Somaini, Roberto Fumagalli.   

Abstract

BACKGROUND AND
OBJECTIVE: Xenon anaesthesia may have the potential to reduce postoperative cognitive impairment after general anaesthesia. This randomized double-blind controlled trial was designed to compare the early postoperative cognitive recovery after xenon and sevoflurane anaesthesia.
METHODS: After institutional ethics approval, we obtained informed written consent from 60 adults, with American Society of Anesthesiologists I or II status, scheduled for elective surgery with an estimated surgery time between 60 and 360 min. Patients were randomized to receive xenon or sevoflurane anaesthesia. Both groups received a remifentanil infusion adjusted to clinical needs based on patients' haemodynamic and state entropy of less than 60. In cases of state entropy of at least 60 during the first 15 min after induction, patients in the xenon group received a propofol infusion targeted to state entropy of less than 60. The primary end-point of the study was the early postoperative cognitive recovery evaluated by the Short Orientation Memory Concentration Test.
RESULTS: There was no significant difference in the mean preoperative Short Orientation Memory Concentration Test values between groups (sevoflurane 2.7 +/- 3.2 and xenon 3.2 +/- 2.6; P, 0.53). Awakening was significantly faster in the xenon group (sevoflurane 8 +/- 4 min and xenon 3 +/- 1 min; P < 0.001). Patients receiving xenon presented significantly lower Short Orientation Memory Concentration Test scores at 30 min (sevoflurane 6.7 +/- 5.9 and xenon 3.3 +/- 3.1; P 0.003) and 60 min (xenon 2.1 +/- 3 and sevoflurane 5 +/- 4.1; P 0.003) after extubation.
CONCLUSION: Xenon anaesthesia was associated with faster emergence and with better early postoperative cognitive recovery than sevoflurane anaesthesia.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20523212     DOI: 10.1097/EJA.0b013e32833b652d

Source DB:  PubMed          Journal:  Eur J Anaesthesiol        ISSN: 0265-0215            Impact factor:   4.330


  7 in total

Review 1.  Noble gases as cardioprotectants - translatability and mechanism.

Authors:  Kirsten F Smit; Nina C Weber; Markus W Hollmann; Benedikt Preckel
Journal:  Br J Pharmacol       Date:  2015-01-12       Impact factor: 8.739

Review 2.  Perioperative neurocognitive disorders: A narrative review focusing on diagnosis, prevention, and treatment.

Authors:  Hao Kong; Long-Ming Xu; Dong-Xin Wang
Journal:  CNS Neurosci Ther       Date:  2022-06-01       Impact factor: 7.035

3.  Cerebral oxygen saturation is improved by xenon anaesthesia during carotid clamping.

Authors:  G Godet; A Couaud; A Lucas; A Cardon; H Beloeil; C Ecoffey
Journal:  HSR Proc Intensive Care Cardiovasc Anesth       Date:  2013

Review 4.  Nitrous oxide-based techniques versus nitrous oxide-free techniques for general anaesthesia.

Authors:  Rao Sun; Wen Qin Jia; Peng Zhang; KeHu Yang; Jin Hui Tian; Bin Ma; Yali Liu; Run H Jia; Xiao F Luo; Akira Kuriyama
Journal:  Cochrane Database Syst Rev       Date:  2015-11-06

5.  Xenon for the prevention of postoperative delirium in cardiac surgery: study protocol for a randomized controlled clinical trial.

Authors:  Layth Al Tmimi; Marc Van de Velde; Paul Herijgers; Bart Meyns; Geert Meyfroidt; Koen Milisen; Steffen Fieuws; Mark Coburn; Koen Poesen; Steffen Rex
Journal:  Trials       Date:  2015-10-09       Impact factor: 2.279

6.  Clinical efficacy of xenon versus propofol: A systematic review and meta-analysis.

Authors:  Yimeng Xia; Hongwei Fang; Jindong Xu; Chenfei Jia; Guorong Tao; Buwei Yu
Journal:  Medicine (Baltimore)       Date:  2018-05       Impact factor: 1.889

Review 7.  Update of the organoprotective properties of xenon and argon: from bench to beside.

Authors:  Roehl Anna; Rossaint Rolf; Coburn Mark
Journal:  Intensive Care Med Exp       Date:  2020-02-24
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.